Comparison of serum protein carbonyl content and ischemia modified albumin in chronic heart failure

Abstract

Protein carbonyl (PC) and Ischemia modified albumin (IMA) are categorized as oxidatively modified protein and have been shown to be biomarkers for diagnosis, prognosis, and monitoring in cardiovascular diseases. However, the roles of these two proteins as prognostic and monitoring marker have never been investigated. This study aimed to determine the level of serum PC content and IMA in patients with chronic heart failure (CHF), who classified following the New York Heart Association (NYHA), compared to healthy subjects. The serum PC content was determined by Spectrophotometric DNPHassay, while serum IMA level was determined by albumin cobalt binding assay. The results showed that the PC content level in all CHF classes was significantly higher than that of healthy subjects (P < 0.001) and there were not significantly different between functional classes. In addition, the serum IMA level was not different in all subject groups (P > 0.05) and not correlated with serum PC content level. In conclusion, the serum PC content level found to have better performance than IMA to discriminate healthy subject from CHF, but insufficient to be used as prognostic marker.

Keywords:  Chronic heart failure,  Protein carbonyl,  Ischemia modified albumin